Drug Trial Radar · NCT05905055
P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales
Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
126
Actual
Start
Sep 22, 2023
Primary completion
Sep 1, 2025
Study completion Sep 1, 2025
Sponsor
- Lead sponsor
- Meiji Seika Pharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multi-center, randomized, single-blind, parallel-group study to assess the efficacy and safety, when nacubactam is coadministered with cefepime or aztreonam, compared with best available therapy (BAT), in the treatment of patients with cUTI, AP, HABP, VABP, and cIAI, due to Carbapenem Resistant Enterobacterales.
Conditions
- Complicated Urinary Tract Infection
- Acute Pyelonephritis
- Hospital-acquired Bacterial Pneumonia
- Ventilator-associated Bacterial Pneumonia
- Complicated Intra-abdominal Infection
Interventions
co-administration of cefepime and nacubactamDrug
2 g cefepime and 1 g nacubactam every 8 hours for at least 5 days and up to 14 days via IV infusion over a period of 60 minutes
co-administration of aztreonam and nacubactamDrug
2 g aztreonam and 1 g nacubactam every 8 hours for at least 5 days and up to 14 days via IV infusion over a period of 60 minutes
BATDrug
Dosage of BAT will be based per site's standard of care
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary efficacy endpoint is the proportion of patients with overall treatment success at TOC across all infection types (ie, cUTI, AP, HABP, VABP, and cIAI), which is a composite endpoint derived from the efficacy outcomes of each infection type.Time frame: TOC (Test of Cure visit): 7 [±2] days after EOT (end of treatment) [Day 10 to 23 after the start of treatment]
Locations
54 sites in 14 countries. Site status is shown where the registry gives one.
Meiji Research Site
Changsha, China
Meiji Research Site
Chongqing, China
Meiji Research Site
Fuyang, China
Meiji Research Site
Guangzhou, China
Meiji Research Site
Hangzhou, China
Meiji Research Site
Hefei, China
Meiji Research Site
Nanjing, China
Meiji Research Site
Nanning, China
Meiji Research Site
Quanzhou, China
Meiji Research Site
Shanghai, China
Meiji Research Site
Shenzhen, China
Meiji Research Site
Shijiazhuang, China
Meiji Research Site
Wuxi, China
Meiji Research Site
Xuzhou, China
Meiji Research Site
Zagreb, Croatia
Meiji Research Site
Kyjov, Czechia
Meiji Research Site
Limoges, France
Meiji Research Site
Nîmes, France
Meiji Research Site
Paris, France
Meiji Research Site
Strasbourg, France
Meiji Research Site
Kutaisi, Georgia
Meiji Research Site
Tbilisi, Georgia
Meiji Research Site
Zestaponi, Georgia
Meiji Research Site
Athens, Greece
Meiji Research Site
Be’er Ya‘aqov, Israel
Meiji Research Site
Ramat Gan, Israel
Meiji Research Site
Tel Aviv, Israel
Meiji Research Site
Hiroshima, Japan
Meiji Research Site
Kanazawa, Japan
Meiji Research Site
Nagasaki, Japan
Meiji Research Site
Nankoku, Japan
Meiji Research Site
Ōta-ku, Japan
Meiji Research Site
Shinjuku-ku, Japan
Meiji Research Site
Toyoake, Japan
Meiji Research Site
Nankoku, Kochi, Japan
Meiji Research Site
Daugavpils, Latvia
Meiji Research Site
Liepāja, Latvia
Meiji Research Site
Riga, Latvia
Meiji Research Site
Valmiera, Latvia
Meiji Research Site
Nitra, Slovakia
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.